<p>Centessa Pharmaceuticals PLC 贊助的 ADR（NASDAQ:CNTA - 獲取免費報告）已獲得目前覆蓋該股票的十二家研究公司的共識推薦為 “適度買入”，Marketbeat 報道。一位投資分析師對該股票給予了賣出評級，十位分析師給予了買入評級，還有一位給予了強烈買入評級。在過去一年中，更新了對該股票覆蓋的經紀公司平均 12 個月目標價為 33.1111 美元。</p>
<ul>
<li>關注這隻生物科技股票，它仍然具有巨大的潛在上漲空間</li>
</ul>
<p>多家股票分析師對 CNTA 股票進行了評論。Guggenheim 在 10 月 6 日的報告中重申了 “買入” 評級，並將 Centessa Pharmaceuticals 的目標價設定為 28.00 美元。Truist Financial 在 11 月 5 日的研究報告中將 Centessa Pharmaceuticals 的目標價設定為 30.00 美元。華爾街禪在 10 月 27 日的報告中將 Centessa Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。Stephens 在 10 月 28 日的研究報告中開始覆蓋 Centessa Pharmaceuticals 的股票。他們給予了 “增持” 評級，併為該公司設定了 35.00 美元的目標價。最後，Chardan Capital 在 8 月 12 日的研究報告中重申了 “買入” 評級，併為 Centessa Pharmaceuticals 的股票設定了 30.00 美元的目標價。</p>
<p><strong>閲讀我們關於 Centessa Pharmaceuticals 的最新股票分析</strong></p>
<h2>Centessa Pharmaceuticals 的內部交易</h2>
<p>在其他新聞中，內部人士 Mario Alberto Accardi 於 9 月 16 日星期二出售了 8,172 股公司的股票。該股票以平均價格 21.40 美元出售，總價值為 174,880.80 美元。出售完成後，該內部人士直接持有 197,394 股公司的股票，價值為 4,224,231.60 美元。這代表了他們持股比例的 3.98% 的下降。該交易已在提交給證券交易委員會的文件中披露，文件可在此鏈接查看。此外，首席技術官 Tia L. Bush 於 11 月 12 日星期三出售了 40,000 股股票。該股票以平均價格 26.00 美元出售，總價值為 1,040,000.00 美元。出售完成後，首席技術官直接持有 121,503 股公司的股票，價值約為 3,159,078 美元。這代表了他們持股比例的 24.77% 的下降。該銷售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士總共出售了價值 4,106,481 美元的 179,964 股公司股票。內部人士持有公司股票的 7.09%。</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者和對沖基金最近修改了對公司的持股。Caitong International Asset Management Co. Ltd 在第一季度將其在 Centessa Pharmaceuticals 的股份增加了 15,209.5%。Caitong International Asset Management Co. Ltd 現在擁有 3,215 股公司的股票，價值 46,000 美元，此前在該期間又購買了 3,194 股。Osterweis Capital Management Inc. 在第一季度購買了 Centessa Pharmaceuticals 的新股份，價值約為 47,000 美元。紐約梅隆銀行在第一季度獲得了 Centessa Pharmaceuticals 的新職位，價值約為 147,000 美元。Fox Run Management L.L.C. 在第一季度購買了 Centessa Pharmaceuticals 的新職位，價值約為 160,000 美元。最後，Vestal Point Capital LP 在第一季度獲得了 Centessa Pharmaceuticals 的新股份，價值 214,000 美元。機構投資者和對沖基金持有公司股票的 82.01%。</p>
<h2>Centessa Pharmaceuticals 股票下跌 1.1%</h2>
<p>NASDAQ CNTA 的股票在星期二開盤價為 27.32 美元。該公司的市值為 36.7 億美元，市盈率為-14.93，貝塔係數為 1.56。公司的 50 日簡單移動平均為 23.36 美元，200 日簡單移動平均為 17.65 美元。公司的速動比率為 10.57，流動比率為 10.56，債務股本比率為 0.36。Centessa Pharmaceuticals 的 52 周低點為 9.60 美元，52 周高點為 29.29 美元。</p>
<p>Centessa Pharmaceuticals（NASDAQ:CNTA - 獲取免費報告）最後一次發佈季度財報是在 11 月 5 日星期三。該公司報告的每股收益為（0.41 美元），低於共識預期的（0.39 美元）0.02 美元。股票分析師預測 Centessa Pharmaceuticals 本財年的每股收益為-1.6。</p>
<h2>Centessa Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Centessa Pharmaceuticals plc 是一家臨牀階段的製藥公司，致力於為患者發現、開發和提供藥物。其產品管線包括 SerpinPC，一種用於治療 A 型和 B 型血友病的活化蛋白 C 抑制劑；以及 ORX750，一種用於治療嗜睡症和其他睡眠障礙的口服 OX2R 激動劑。</p>
<h2>精選故事</h2>
<ul>
<li>我們更喜歡的五隻股票超過 Centessa Pharmaceuticals</li>
<li>市值計算器：如何計算市值</li>
<li>惠而浦的最糟糕時期可能已經過去——未來有上漲機會</li>
<li>什麼是日經 225 指數？</li>
<li>這三隻被打壓的股票可能是你本季度最佳的購買機會</li>
<li>現在購買的三隻沃倫·巴菲特股票</li>
<li>D-Wave 在財報季後與量子競爭對手相比如何？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Centessa Pharmaceuticals 嗎？</h2>
<p>在考慮 Centessa Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Centessa Pharmaceuticals 並不在名單上。</p>
<p>雖然 Centessa Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CNTA

<p>Centessa Pharmaceuticals PLC（納斯達克代碼：CNTA）獲得了十二家研究公司的 “適度買入” 共識評級。分析師設定的 12 個月平均目標價為 33.11 美元。最近的內部交易包括 Mario Alberto Accardi 和首席技術官 Tia L. Bush 的股票出售。機構投資者持有該公司 82.01% 的股份。Centessa Pharmaceuticals 報告的季度每股虧損為 0.41 美元，低於預期 0.02 美元</p>

<p>Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) have received a consensus recommendation of &#34;Moderate Buy&#34; from the twelve research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $33.1111.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals PLC 贊助的 ADR（NASDAQ:CNTA - 獲取免費報告）已獲得目前覆蓋該股票的十二家研究公司的共識推薦為 “適度買入”，Marketbeat 報道。一位投資分析師對該股票給予了賣出評級，十位分析師給予了買入評級，還有一位給予了強烈買入評級。在過去一年中，更新了對該股票覆蓋的經紀公司平均 12 個月目標價為 33.1111 美元。</p>
</div><ul>
<li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>關注這隻生物科技股票，它仍然具有巨大的潛在上漲空間</li>
</ul>
</div><p>A number of equities analysts have commented on CNTA shares. Guggenheim reissued a &#34;buy&#34; rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Truist Financial set a $30.00 price target on Centessa Pharmaceuticals in a research report on Wednesday, November 5th. Wall Street Zen upgraded Centessa Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 27th. Stephens began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They issued an &#34;overweight&#34; rating and a $35.00 target price for the company. Finally, Chardan Capital reissued a &#34;buy&#34; rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Tuesday, August 12th.</p>
<div class="lb-trans"><p>多家股票分析師對 CNTA 股票進行了評論。Guggenheim 在 10 月 6 日的報告中重申了 “買入” 評級，並將 Centessa Pharmaceuticals 的目標價設定為 28.00 美元。Truist Financial 在 11 月 5 日的研究報告中將 Centessa Pharmaceuticals 的目標價設定為 30.00 美元。華爾街禪在 10 月 27 日的報告中將 Centessa Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。Stephens 在 10 月 28 日的研究報告中開始覆蓋 Centessa Pharmaceuticals 的股票。他們給予了 “增持” 評級，併為該公司設定了 35.00 美元的目標價。最後，Chardan Capital 在 8 月 12 日的研究報告中重申了 “買入” 評級，併為 Centessa Pharmaceuticals 的股票設定了 30.00 美元的目標價。</p>
</div><p><strong>Read Our Latest Stock Analysis on Centessa Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Centessa Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Insider Transactions at Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 的內部交易</h2>
</div><p>In other news, insider Mario Alberto Accardi sold 8,172 shares of the company's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $21.40, for a total value of $174,880.80. Following the completion of the sale, the insider directly owned 197,394 shares in the company, valued at $4,224,231.60. This represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CTO Tia L. Bush sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the completion of the sale, the chief technology officer directly owned 121,503 shares of the company's stock, valued at approximately $3,159,078. This represents a 24.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 179,964 shares of company stock worth $4,106,481 in the last ninety days. Insiders own 7.09% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Mario Alberto Accardi 於 9 月 16 日星期二出售了 8,172 股公司的股票。該股票以平均價格 21.40 美元出售，總價值為 174,880.80 美元。出售完成後，該內部人士直接持有 197,394 股公司的股票，價值為 4,224,231.60 美元。這代表了他們持股比例的 3.98% 的下降。該交易已在提交給證券交易委員會的文件中披露，文件可在此鏈接查看。此外，首席技術官 Tia L. Bush 於 11 月 12 日星期三出售了 40,000 股股票。該股票以平均價格 26.00 美元出售，總價值為 1,040,000.00 美元。出售完成後，首席技術官直接持有 121,503 股公司的股票，價值約為 3,159,078 美元。這代表了他們持股比例的 24.77% 的下降。該銷售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士總共出售了價值 4,106,481 美元的 179,964 股公司股票。內部人士持有公司股票的 7.09%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its stake in Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after purchasing an additional 3,194 shares during the period. Osterweis Capital Management Inc. purchased a new stake in shares of Centessa Pharmaceuticals during the 1st quarter valued at approximately $47,000. Bank of New York Mellon Corp acquired a new position in Centessa Pharmaceuticals in the first quarter valued at approximately $147,000. Fox Run Management L.L.C. purchased a new position in Centessa Pharmaceuticals in the first quarter worth approximately $160,000. Finally, Vestal Point Capital LP acquired a new stake in Centessa Pharmaceuticals during the first quarter worth $214,000. Institutional investors and hedge funds own 82.01% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近修改了對公司的持股。Caitong International Asset Management Co. Ltd 在第一季度將其在 Centessa Pharmaceuticals 的股份增加了 15,209.5%。Caitong International Asset Management Co. Ltd 現在擁有 3,215 股公司的股票，價值 46,000 美元，此前在該期間又購買了 3,194 股。Osterweis Capital Management Inc. 在第一季度購買了 Centessa Pharmaceuticals 的新股份，價值約為 47,000 美元。紐約梅隆銀行在第一季度獲得了 Centessa Pharmaceuticals 的新職位，價值約為 147,000 美元。Fox Run Management L.L.C. 在第一季度購買了 Centessa Pharmaceuticals 的新職位，價值約為 160,000 美元。最後，Vestal Point Capital LP 在第一季度獲得了 Centessa Pharmaceuticals 的新股份，價值 214,000 美元。機構投資者和對沖基金持有公司股票的 82.01%。</p>
</div><h2>Centessa Pharmaceuticals Stock Down 1.1%</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 股票下跌 1.1%</h2>
</div><p>Shares of NASDAQ CNTA opened at $27.32 on Tuesday. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -14.93 and a beta of 1.56. The company's 50-day simple moving average is $23.36 and its 200-day simple moving average is $17.65. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 52-week low of $9.60 and a 52-week high of $29.29.</p>
<div class="lb-trans"><p>NASDAQ CNTA 的股票在星期二開盤價為 27.32 美元。該公司的市值為 36.7 億美元，市盈率為-14.93，貝塔係數為 1.56。公司的 50 日簡單移動平均為 23.36 美元，200 日簡單移動平均為 17.65 美元。公司的速動比率為 10.57，流動比率為 10.56，債務股本比率為 0.36。Centessa Pharmaceuticals 的 52 周低點為 9.60 美元，52 周高點為 29.29 美元。</p>
</div><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Equities analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（NASDAQ:CNTA - 獲取免費報告）最後一次發佈季度財報是在 11 月 5 日星期三。該公司報告的每股收益為（0.41 美元），低於共識預期的（0.39 美元）0.02 美元。股票分析師預測 Centessa Pharmaceuticals 本財年的每股收益為-1.6。</p>
</div><h2>Centessa Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals plc 是一家臨牀階段的製藥公司，致力於為患者發現、開發和提供藥物。其產品管線包括 SerpinPC，一種用於治療 A 型和 B 型血友病的活化蛋白 C 抑制劑；以及 ORX750，一種用於治療嗜睡症和其他睡眠障礙的口服 OX2R 激動劑。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Centessa Pharmaceuticals</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Whirlpool’s Worst May Be Over—Upside Opportunity Ahead</li>
<li>What is the Nikkei 225 index?</li>
<li>These 3 Beaten-Down Stocks Could Be Your Best Buying Opportunity This Quarter</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>How Does D-Wave Stack Up to Quantum Rivals After Earnings Season?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票超過 Centessa Pharmaceuticals</li>
<li>市值計算器：如何計算市值</li>
<li>惠而浦的最糟糕時期可能已經過去——未來有上漲機會</li>
<li>什麼是日經 225 指數？</li>
<li>這三隻被打壓的股票可能是你本季度最佳的購買機會</li>
<li>現在購買的三隻沃倫·巴菲特股票</li>
<li>D-Wave 在財報季後與量子競爭對手相比如何？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Centessa Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Centessa Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Centessa Pharmaceuticals 並不在名單上。</p>
</div><p>While Centessa Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Centessa Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Centessa Pharmaceuticals PLC 贊助的美國存託憑證（NASDAQ:CNTA）獲得分析師一致評級為 “適度買入”